Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27323725 | 0.91 | KCNH2 (0.36) | SIGMAR1 | |
| SCHEMBL27323728 | 0.91 | KCNH2 (0.36) | SIGMAR1 | |
| SCHEMBL27323721 | 0.91 | KCNH2 (0.36) | SIGMAR1 | |
| SCHEMBL17702046 | 0.89 | HRH3 (0.42) | HRH3SIGMAR1 | |
| SCHEMBL19098600 | 0.84 | HRH3 (0.35) | HRH3SIGMAR1 | |
| SCHEMBL18233622 | 0.81 | NCF1 (0.38) | SIGMAR1 | |
| SCHEMBL17788463 | 0.81 | HRH3 (0.34) | HRH3 | |
| SCHEMBL24233179 | 0.79 | HRH3 (0.38) | HRH3SIGMAR1 | |
| SCHEMBL25122577 | 0.79 | HRH3 (0.40) | HRH3SIGMAR1 | |
| SCHEMBL17036641 | 0.77 | SLC6A4 (0.32) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | HRH3 3874/4885SIGMAR1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.